Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research Article

A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate

TORU KANEKO, SHIGENORI GOTO, YOSHIAKI KUSHIMA, YOJU MIYAMOTO, MASAZUMI ERIGUCHI, MIE NIEDA and KOJI EGAWA
Anticancer Research September 2004, 24 (5C) 3303-3310;
TORU KANEKO
1Shin-yokohama Medical Clinic, Usui building 3F, 2-5-14 Shin-yokohama, Kohoku-ku, Yokohama-shi, Kanagawa 222-0033
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGENORI GOTO
2Seta clinic, 4-20-18 Seta, Setagaya-ku, Tokyo 158-0095
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIAKI KUSHIMA
3Ryutoku-kai Medical Corp. Tsuruta Hospital, 1-78 Mifune-cho, Saito-shi, Miyazaki 881-0016
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOJU MIYAMOTO
1Shin-yokohama Medical Clinic, Usui building 3F, 2-5-14 Shin-yokohama, Kohoku-ku, Yokohama-shi, Kanagawa 222-0033
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAZUMI ERIGUCHI
1Shin-yokohama Medical Clinic, Usui building 3F, 2-5-14 Shin-yokohama, Kohoku-ku, Yokohama-shi, Kanagawa 222-0033
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIE NIEDA
4Institute of Medical Science, Medinet Inc., 2-2-8 Tamagawadai, Setagaya-ku, Tokyo 158-0096, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI EGAWA
4Institute of Medical Science, Medinet Inc., 2-2-8 Tamagawadai, Setagaya-ku, Tokyo 158-0096, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Immunocell therapy has been applied to patients with refractory cancer in clinical trials or as an unconventional cancer therapy, however the efficacy is still limited. To improve this efficacy, a combination therapy may be beneficial. Molecularly-targeted therapy acts directly on neoplasm cells to suppress their growth without causing myelosuppression. Case Report: Recently, we encountered three patients treated by immunocell therapy with imatinib mesylate (Glivec®). One patient was diagnosed as having Philadelphia chromosome (Ph) (+) acute lymphoblastic leukemia (ALL) and had a relapse-free survival of more than 24 months. The other two were diagnosed as having GIST; a partial response was observed in one which lasted more than 21 months, while the other's disease has been stabilized for more than 25 months. No side-effects were observed, other than those mentioned in the directions for the use of imatinib. Conclusion: Immunocell therapy may have a potent therapeutic effect when used in combination with molecularly-targeted therapy, which has few side-effects.

  • Received June 30, 2004.
  • Accepted July 25, 2004.
  • Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 24 (5C)
Anticancer Research
Vol. 24, Issue 5C
September-October 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate
TORU KANEKO, SHIGENORI GOTO, YOSHIAKI KUSHIMA, YOJU MIYAMOTO, MASAZUMI ERIGUCHI, MIE NIEDA, KOJI EGAWA
Anticancer Research Sep 2004, 24 (5C) 3303-3310;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate
TORU KANEKO, SHIGENORI GOTO, YOSHIAKI KUSHIMA, YOJU MIYAMOTO, MASAZUMI ERIGUCHI, MIE NIEDA, KOJI EGAWA
Anticancer Research Sep 2004, 24 (5C) 3303-3310;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Anticancer Research

© 2021 Anticancer Research

Powered by HighWire